Published in Rev Endocr Metab Disord on March 01, 2016
Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J (2016) 0.75
Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases. Visc Med (2016) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
A core gut microbiome in obese and lean twins. Nature (2008) 52.30
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Inflammation and metabolic disorders. Nature (2006) 33.33
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 27.52
Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med (2013) 20.98
Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 20.57
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med (2006) 18.51
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015) 11.05
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Mechanisms linking obesity with cardiovascular disease. Nature (2006) 9.07
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 6.93
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet (2007) 6.80
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med (2015) 6.48
Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 6.04
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
The metabolic syndrome. Endocr Rev (2008) 5.33
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12
A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med (2009) 4.80
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. N Engl J Med (2015) 4.35
Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature (2014) 4.28
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr (1956) 4.11
Platelets in inflammation and atherogenesis. J Clin Invest (2005) 4.10
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (2015) 3.66
Dietary intervention impact on gut microbial gene richness. Nature (2013) 3.56
Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension (2007) 3.40
Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab (2007) 3.33
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol (2012) 3.09
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J (2004) 2.96
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation (2003) 2.80
Transcriptional control of brown adipocyte development and physiological function--of mice and men. Genes Dev (2009) 2.66
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab (2012) 2.46
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest (2006) 2.40
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ (2011) 2.40
Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med (1993) 2.35
Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell (2015) 2.20
Changes in serum potassium mediate thiazide-induced diabetes. Hypertension (2008) 2.09
The microbiome of uncontacted Amerindians. Sci Adv (2015) 2.04
Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension (2001) 2.04
Metabolic consequences of stress during childhood and adolescence. Metabolism (2011) 2.04
Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology (2014) 1.81
Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet (2013) 1.73
Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest (1996) 1.60
Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham Heart Study. Atherosclerosis (2010) 1.60
Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation (2011) 1.59
A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension (2012) 1.54
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes (2005) 1.52
The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia (2001) 1.51
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med (2013) 1.51
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Genetics of the metabolic syndrome. Appl Physiol Nutr Metab (2007) 1.36
Epicardial perivascular adipose-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway. Arterioscler Thromb Vasc Biol (2010) 1.35
Safety considerations with fibrate therapy. Am J Cardiol (2006) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol (2002) 1.30
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) (2006) 1.28
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes (2005) 1.25
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet (2015) 1.23